Methods
This retrospective cohort analysis was performed on all adult cystic
fibrosis patients that were admitted at a tertiary care facility for
treatment of APE and with tobramycin between January 2015 and December
2019. The primary objective was to evaluate the predictive performance
of previously published pharmacokinetic (PK) models and, secondly, to
evaluate potential factors that impact clinical outcomes. Clinical
outcomes were only evaluated in a sub-group of patients with cultures
positive for P. aeruginosa .